Kim, AeRang <br/><br/>
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.  [electronic resource] 

 -  Pediatric blood & cancer  Mar 2013 
 - 396-401 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.24281  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Agents--administration & dosage<br/>Child<br/>Child, Preschool<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Neurofibroma, Plexiform--drug therapy<br/>Neurofibromatosis 1--complications<br/>Niacinamide--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Sorafenib